Stockreport

ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program

Opko Health, Inc.  (OPK) 
Last opko health, inc. earnings: 2/26 04:05 pm Check Earnings Report
US:NYSE Investor Relations: investor.opko.com
PDF Brings total awards from BARDA to $110 million for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of up to $205 million if all opti [Read more]